Conference MDAngle: AUA 2024 Metastatic Prostate Cancer

2 weeks ago 6

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients.

The American Urological Association 2024 Annual Meeting will be held May 3-6 in San Antonio, Texas. Anticipated sessions in the realm of advancements in metastatic prostate cancer include updated guidance on molecular imaging from new joint AUA/ASTRO/SUO guidelines on Salvage Therapy for Prostate Cancer. Other expected topics encompass molecular imaging like PSMA PET, immunotherapy with PARP inhibitors, and updates on trials such as the VISION study, focusing on lutetium-based therapies in combination with anti-androgens. Additionally, updates on the TARGET trial highlighting the value of genetic testing, and the PROpel study evaluating olaparib plus abiraterone are expected.

Kelvin Moses, MD, PhD

Associate Professor, Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee

“AUA 2024 promises to be quite exciting in the world of metastatic prostate cancer. There have been several trials and updates to previous trials that have come out in the last couple of months, and I expect to hear some of that at AUA.”

Mohammed Mahmoud, MD

Assistant Professor, Division of Urology, Southern Illinois University School of Medicine, Springfield, Illinois

“I'm excited about two new programs at AUA 2024. The first one is P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology, and the second one is Clinical Trials in Progress. Both programs were designed to showcase exceptional studies that are expected to change clinical practice and hopefully, ultimately, benefit our patients.”

Preconference Considerations

AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer

In anticipation of AUA 2024, Dr Moses shares his excitement about the upcoming conference and highlights some areas he is eager to explore. These include updates on PSMA PET imaging, new data on PARP inhibitors, and updates from trials evaluating combination therapies.